JPMorgan analyst Lisa Gill views the 19% pullback since March 21 in shares of Teladoc as a buying opportunity. The analyst does not have a fundamental reason to point to for the selloff and believes the company's underlying fundamentals are unchanged. Gill has heard some concerns following the Forbes article earlier this week that questioned Teladoc's use of an adjusted EBITDA metric. She notes, however, that nearly all of the companies within her coverage universe focus investors on an adjusted EBITDA or adjusted EBIT. With the acquisitions that Teladoc has done over the past few years, amortization has grown significantly, and excluding that helps to better understand the underlying growth of the business, Gill tells investors in a research note. The analyst continues to see "significant runway" in the telehealth space going forward and keeps an Overweight rating on Teladoc with an $80 price target.

Reports Q1 revenue $646.13M, consensus $637.29M. "We are pleased to report a solid start to the year, with strength in both revenue and adjusted EBITDA in the first quarter," said Mala Murthy, acting chief executive officer and chief financial officer of Teladoc Health. "During this period of transition, our team remains laser focused on our key initiatives, which include building upon our market leadership position; driving increased product penetration through our large installed base of over 90 million virtual care members; and accelerating our bottom-line performance."